Market Place
Sourcing Support
Progentos emerges with $65M for multiple sclerosis trials with IP from Frequency
20 May 2024 //
ENDPTS
Korro Bio and Frequency Therapeutics Announce Closing of Merger
03 Nov 2023 //
GLOBENEWSWIRE
Frequency Therapeutics Provides Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Korro Bio and Frequency Therapeutics Announce Merger Agreement
14 Jul 2023 //
BUSINESSWIRE
Frequency Provides Fourth Quarter and Full Year 2022 Financial Results
10 Mar 2023 //
BUSINESSWIRE
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
27 Feb 2023 //
BUSINESSWIRE
Frequency to cut jobs after clinical trial setback
14 Feb 2023 //
BIOPHARMADIVE
Frequency doses first patient in Phase Ib sensorineural hearing loss trial
16 Dec 2022 //
CLINICALTRIALSARENA
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345
15 Dec 2022 //
BUSINESSWIRE
Frequency to Host Event, Highlighting Hearing Restoration Candidate FX-322
17 Nov 2022 //
BUSINESSWIRE
Frequency Therapeutics Provides Business Updates and3Q 2022 Financial Results
08 Nov 2022 //
BUSINESSWIRE
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322
12 Oct 2022 //
BUSINESSWIRE
Frequency Therapeutics to Participate in Sept Investor and Medical Conferences
30 Aug 2022 //
BUSINESSWIRE
Frequency Therapeutics Provides Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Frequency Therapeutics Provides Business Updates and Q1 2022 Financial Results
04 May 2022 //
BUSINESSWIRE
Frequency Tx Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
BUSINESSWIRE
Frequency Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study
09 Dec 2021 //
BUSINESSWIRE
Frequency Therapeutics Provides Business Updates and Q3 2021 Financial Results
15 Nov 2021 //
BUSINESSWIRE
Frequency Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322
09 Nov 2021 //
BUSINESSWIRE
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances
27 Oct 2021 //
BUSINESSWIRE
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b
21 Oct 2021 //
BUSINESSWIRE
Frequency Therapeutics Announces New FX-322 Results Showing Hearing Improvements
22 Sep 2021 //
BUSINESSWIRE
Frequency Releases New Data from Two FX-322 Clinical Studies
23 Mar 2021 //
BUSINESSWIRE
Frequency Releases New Data from Two FX-322 Clinical Studies
23 Mar 2021 //
BUSINESSWIRE
Frequency regroups as hearing loss med falls short in phase 2
23 Mar 2021 //
FIERCEBIOTECH
Frequency Announces Publication of Phase 1/2 Data Showing Hearing Improvements
22 Feb 2021 //
BUSINESSWIRE
Frequency Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer
19 Jan 2021 //
BUSINESSWIRE
Frequency Therapeutics to Host Investor Event on the Potential for Restorative
18 Dec 2020 //
BUSINESSWIRE
Frequency Announces Expanded FX-322 Clinical DEV Program Day-90 Ph2a
30 Oct 2020 //
BIOSPACE
Frequency Announces Expanded FX-322 Clinical Development Program Day-90 Ph 2a
30 Oct 2020 //
BUSINESSWIRE
Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study
22 Sep 2020 //
BUSINESSWIRE
Frequency`s hearing loss treatment shows long-term promise
15 Sep 2020 //
FIERCEBIOTECH
Frequency Therap. shows Improvement in Hearing Loss Patients Treated with FX-322
13 Sep 2020 //
BUSINESSWIRE
Frequency Therapeutics Announces $42 Million Private Placement
17 Jul 2020 //
BUSINESSWIRE
Frequency Therapeutics to Present at Upcoming Investor Conferences
26 May 2020 //
BUSINESSWIRE
Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322
10 Oct 2019 //
BUSINESS WIRE
